anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing capsaicine glycosides ensuring food safety in the production process and to provide a safe use form of the capsaicine.  &lt;P&gt;SOLUTION: The method biochemically produces the glycosides of capsaicines. The capsaicines comprises for example, capsaicine, 8-nordihydrocapsaicine. The capsaicine is subjected to a glycoside formation to produce capsaicine-beta- D-glycopyranoside by using a cultured cell of a vegetable stem such as Pytolacca Americana. The 8-nordihydrocapsaicine is subjected to the glycoside formation for forming 8-nordihydrocapsaicine-beta-D-glycopyranoside by the cultured cell of the vegetable. The capsaicines such as the capsaicine, the 8- nordihydrocapsaicine, are subjected to the glycoside formation by using an enzyme such as CGTase.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To invalidate prescription order information of medicine for dosing which has becomes unnecessary.  &lt;P&gt;SOLUTION: A prescription order issuing section 11 issues prescription order information and stores it in a prescription order database 10. If the prescription order information is for a medicine for dosing, a corresponding disease name decision section 13 stores a correspondence disease name designated by a user in the prescription order database 10. If an outcome input process is performed in a chart database 2, a prescription order invalidating section 15 obtains outcome information, including a patient ID and the name of the disease of outcome input-processed chart data; extracts prescription order information corresponding to the patient ID and the name of the disease from a prescription order database 2; and urges confirmation of the extracted prescription order. After a confirmation is made by the user, the prescription order information is set to invalidation. A medication indication display processing section 17 displays medication indication, based on the valid prescription order information on a display device 4 at a predetermined date and time.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a hair cosmetic capable of imparting excellent pliability and excellent lubricity to hair and improving the coherency of the hair by including a specific amount of an aliphatic polyvalent carboxylic acid (salt) therein. SOLUTION: This hair cosmetic is obtained by including 1-20 wt.% aliphatic polyvalent carboxylic acid (salt) therein. The hair cosmetic is especially suitable for use in a hair dye. When used as the hair dye, (B) 0.5-20 wt.% aromatic alcohols represented by the formula [R&#39; is H, an alkyl or an alkoxy; X is a 1-4C straight-chain or branched chain alkylene or alkenyl and may contain an ether bond; (p) is 0 or 1] (e.g. benzyl alcohol) is preferably contained. An aliphatic carboxylic acid containing at least &gt;=2 carboxyl groups in the molecule may be used as the ingredient A and hydroxyl group may be contained as a substituent group. Malonic acid, adipic acid, succinic acid, etc., are cited as concrete examples of the aliphatic carboxylic acid.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new peptide and uses thereof.  &lt;P&gt;SOLUTION: This new peptide and a DNA encoding the same are provided. A drug comprising the peptide or DNA and a method for screening/a kit for screening a compound promoting or inhibiting the activity of the peptide or its salt are provided. The compound obtained by the screening or its salt, the drug, etc., comprising the compound or its salt are provided. Thereby, the peptide and DNA encoding the same can be used for, e.g. diagnosis, treatment, prophylaxis, etc., of digestive system diseases, etc. The peptide is useful as a reagent for screening the compound promoting or inhibiting the activity of a receptor protein to which the peptide is capable of binding or its salt.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic, a food or the like which exhibits the inhibition of active oxygen in skins and bodies, an anti-ageing function for freckles, wrinkles and the like, a function for maintaining the health of body, high skin moisture retainability, and a skin-smoothening effect, without deteriorating the original high anti-oxidizing properties of the seaweeds such as Nemacystus decipiens, to provide a method for maturing a seaweed, such as Nemacystus decipiens, to give a main ingredient for the cosmetic and the food, and to provide a method for producing the matured Nemacystus decipiens extract or the matured seaweed.  &lt;P&gt;SOLUTION: This method for producing the matured Nemacystus decipiens comprises washing raw Nemacystus decipiens with water, adding a proper amount of salt to the raw Nemacystus decipiens, enough mixing, and then leaving the mixture in a container or the like. The leaving conditions comprise ordinary temperature or cold air in a room or a dark place. A period for the leaving is one month to several years. The obtained matured Nemacystus decipiens are purified to obtain the matured Nemacystus decipiens extract, and a cosmetic, a food or the like containing the matured Nemacystus decipiens extract is provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The application relates to a medicament carrier which is suitable for the treatment and prevention of pathological conditions in the urogenital region of a person, in particular in the area of the urethra. Said medicament carrier comprises a biocompatible material that cannot melt at the person&#39;s body temperature. The medicament carrier is prepared, e.g. at least partially coated, with an active substance or with a mixture of active substances. The medicament carrier is provided with a recovery string ( 6 ) for removing same from the body orifice after completion of the treatment. Active substances can be administered generally in the urogenital region using the medicament carrier. The medicament carrier can also be used for microbial reconstitution of the urogenital tract and for sterile catheterization.
The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing &amp; collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an isolated mammalian acetylcoenzyme A transporter (AT) protein.  &lt;P&gt;SOLUTION: The isolated mammalian acetylcoenzyme A transporter (AT) protein, anti-AT antibody, therapeutic composition and nucleic acid encoding them are provided. The bioassey and method of treatment by using the protein are also provided. The AT protein is a polypeptide containing a specific sequence recognized specifically by an antibody specifically recognizing the AT protein (preferably human AT). The isolated AT protein does not contain cellular components and/or contaminants usually associated with its natural in vivo environment.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine. SUBSTANCE: new agent is used for treatment treatment of malignant tumors. It is represented by extract of leaves and flowers of common peach (Persica vulgaris mill). New agent advantage consists in prompt rehabilitation of patients and their recovery, as well as in prolongation of patients&#39; life in late stage of tumoral process. EFFECT: enhanced efficiency of treatment. 1 tbl, 7 ex
An improved virus vaccine for canine distemper is obtained by passing canine distemper virus through live chick embryos for a sufficient number of passages to produce avirulence, inoculating the avirulent virus into a culture of chick embryo tissue and incubating and harvesting the resulting vaccine.  Tissues from chick embryos of various ages may be used but tissues from nine day old embryos are preferred.  Trypsinized chick embryo tissues are prepared in a conventional manner and are suspended in a growth medium fluid consisting of Earle&#39;s basal medium containing 0.5% lactalbumin hydrolysate and from 15 to 20% normal calf serum. Insulation was made with the 48th passage of modified canine distemper virus through live chick embryos.  Incubation was for 7 days at 37 DEG  C.  The avirulent virus is passed serially through a plurality of chick embryo tissue cultures and then the harvested vaccine is freeze-dried.  The resultant canine distemper virus is free from contamination with the tissue of the chick embryos.
NEW MATERIAL:A compound expressed by formula I [R is OH, NH2 or OR&#39; (R&#39; is 1-5C alkyl); X is H or OH]. EXAMPLE:Acryloyl-D-proline methyl ester. USE:A compound readily convertible into polymers having stimulation responsiveness function. Since the polymers have a great extent of swelling and shrinking in water and function to respond to microstimulation, such as solvent or temperature, and completely recover to the original swollen or shrunk state in removing the microstimulation, the scope of utilization is extremely wide. For example, the polymers can be used for mixing a physiologically active substance therein and controlling the sustained release properties thereof with the stimulation responsiveness function, etc. PREPARATION:An active ester of acrylic acid, such as acrylic acid chloride, is reacted with a proline derivative expressed by formula II (e.g., proline methyl ester) in a solvent, e.g., dioxan, to afford the compound expressed by formula I.
PROBLEM TO BE SOLVED: To obtain a new specific alanine derivative effective for specifically inhibiting angiotensin converting enzyme, endothelin conversion enzyme and enkephalinase and useful for analgesic, hypotensive diuretic treatment or for the prevention, treatment, etc., of cardiac insufficiency and hypertension. SOLUTION: This new alanine derivative is expressed by the formula I [R&lt;1&gt; is OH, a lower alkoxy or a lower aralkyloxy; R&lt;2&gt; is H, a lower alkyl or a lower aralkyl; R&lt;3&gt; is a lower alkyl; R&lt;4&gt; is OH or a lower aralkyl; Ar is an aryl such as a (substituted)phenyl, a (substituted)naphthyl, thienyl or pyridyl]. The derivative specifically inhibits the action of a metal peptidase such as angiotensin converting enzyme, endothelin converting enzyme and enkephalinase and is useful for analgesic, antidiarrheic and hypotensive diuretic treatment and the prevention, treatment, etc., of cardiac insufficiency and hypertension.  The compound can be produced by reacting a substituted alanine compound of the formula II with trichloromethyl chloroformate, reacting the product with a compound of the formula III (R&lt;8&gt; is an alkoxy, etc.; R&lt;9&gt; is an alkyl, etc.) and finally hydrolyzing the reaction product.
The invention discloses a method, a device and a system for extracting time compound words from medical texts, and particularly relates to the technical field of natural language processing information extraction. The invention comprises a reading module, a calculating module and a display module. The reading module mainly refers to a system for reading medical texts. The calculation module comprises a time compound word extraction unit, a time compound word updating unit and a new time compound word structure extraction unit. The extraction of the time compound words is mainly based on the word formation method of &#39;number words + time collocation words&#39;, and partial time compound word structures need to be manually summarized. The method comprises the following steps: a. reading the medical text; b. extracting time compound words through a time compound word structure; c. and acquiring a time compound word structure through the time compound word. If the result is increased in number compared with the existing entities, the iteration is continued, otherwise, the iteration is ended. The display module includes: a storage unit and an output unit. The method takes the medical text as a starting point, and finally realizes the accurate extraction of the time compound words in the medical text.
Non-peptide molecules of formula (I) may be used to mimic the structure of peptides and to bind with proteins which naturally bind peptide ligands. In said formula, C&#39; is a substituted or unsubstituted carbon atom; X is a C1 to C4 chain in which each of the carbon atoms may be substituted or unsubstituted; and R?1 and R2¿ are groups mimicking the side chains of a natural or unnatural amino acid. The molecules may either be used on their own, or may be incorporated into larger molecules such as polypeptides. In either case, they may be used as therapeutics to alter the activity of the protein. Additionally, they may be used to assay the proteins or to act as affinity ligands in their purification. Methods of manufacturing polypeptides incorporating the molecules of the invention are also described.
336,470. Schering-Kahlbaum Akt.- Ges. Dec. 6, 1928, [Convention, date]. Hormones.-In the purification of crude hormone preparations obtained from body liquids, organs, or vegetable substances such as yeast, maize shoots, &amp;c. impurities of an ester-like nature are saponified by means of Twitchell reagent, Dartring saponifier lipase of castor seed, pancreas lipase, or other catalytically-acting agent. In examples, the treatment of ovarial hormone from placenta, crude extract from maize shoots, and ovarial hormone from the urine of pregnant women is described. The saponified mixture is worked up by extracting with methyl alcohol, neutralizing the extract with alcoholic baxyta, and extracting the filtrate after concentration and taking up in water with ether. The hormone is obtained by evaporating the ethereal solution.
PURPOSE:To obtain lecithin capable of dispersing into water even in the presence of an electrolyte and useful for cosmetic, etc., by preparing an aqueous solution of fine dispersion of a composition consisting of lecithin, polyhydric alcohol and hydrophilic polyoxyethylene alkyl ester, etc., and dehydrating and drying the aqueous solution. CONSTITUTION:The solid or powdery aimed lecithin obtained by preparing an aqueous solution of fine dispersion of composition consisting of (A) lecithin, (B) polyhydric alcohol (e.g. glycerin or glucose) and (C) hydrophilic polyoxyethylenealkyl ester (e.g. polyoxyethylene castor oil) or hydrophilic polyoxyethylenealkyl ether (e.g. phytosterol) and dehydrating and drying the aqueous solution. The weight ratio of the ingredients B/A is preferably 100/1-1/10 and the weight ratio of the ingredients C/A is preferably &lt;=1/3.
The present invention relates to an autonomic-replication-type carrier in human&#39;s liver-cancer cell specific viruses and usage thereof. The autonomic-replication-type carrier is composed of a liver-cancer cell specific promotor namely an alpha-fetoprotein gene promotor, an EB virus plasmid type replicon, a trans-acting factor, a eukaryotic cell resistance selection mark, and an escherichia coli plasmid skeleton with an escherichia coli replicon and an ampicillin resistance gene. The autonomic-replication-type carrier can lead an exogenous gene to be inputted into a cell for autonomic replication in a non-virus infection mode and can only have specific expression in liver-cancer cells which generate alpha fetoprotein. Compared with a mode that a recombined virus particle is directly used for directly leading cells to be infected, the safety is higher. The present invention is mainly used for the gene therapy of a primary liver cancer. Tumour cells can be killed in a selectivity mode, and the functions of normal cells can not be influenced.
Methods, systems and apparatuses are provided for controlling and tracking patient access to medicaments. A patient is provided with medication in locked pill containers that must be unlocked before the patient can access medication. The patient is forced through an interactive session periodically with a master system, via a communicative intermediary, in order to obtain a valid passcode for each batch of medications. The patient may be assessed during each interaction with the master system. That assessment may include questions about status codes displayed on each medication container. These status codes may encode detail about the patient&#39;s pattern of accessing medication. A rate of medication usage can also be deduced from the rate at which the patient contacts the master system. After patient assessment, the master system may elect to not provide the patient with an access code, such as if the assessment indicates overuse of the medication.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a muscle damage-inhibitory composition promising the prevention of having a pulled muscle, muscle pain, etc. and the relief-promoting effects such as recover from muscle fatigue by preventing inflammatory reactions attributable to muscle damage occurring by an excessive exercise or the like to inhibit secondary damage to peripheral tissue as well, and to obtain a muscle damage relief-promoting composition promising e.g. cutting the period of enabling no glycogen loading by promptly relieving muscle damage.  &lt;P&gt;SOLUTION: The muscle damage-inhibitory composition and the muscle damage relief-promoting composition are each obtained by including cacao mass and/or a processed product thereof as active ingredient, wherein the cacao mass and/or its processed product is preferably cocoa powder. In each of these compositions, at least one material selected from lactoprotein, soybean protein and amino acid is preferably contained as other ingredient(s). Further, it is preferable that each of these compositions contain 1 mass% of the cacao mass and/or its processed product and 5 mass% of the other ingredient(s).  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antiobestic agent, a lipolysis promoter, a fat cell differentiation inhibitor, a blood neutral fat increase inhibitor and an adiponectin production promoter that can be daily continuously taken and is highly effective and highly safe.  &lt;P&gt;SOLUTION: The antiobestic agent and the like comprise extracts from devil&#39;s claw. The preparation form can be selected from various kinds of preparation forms, but an internal medicine is preferable, in particular. The dosage depends on the purpose of use, age, body weight and the like, and preferably 0.02-20 mg/kg, and particularly preferably 0.1-10 mg/kg. The agents act on obesity multilaterally to exhibit excellent improving effects and therefore, are useful for pharmaceuticals, quasi-drugs, foods and drinks, cosmetics and the like used for the purpose of prevention and amelioration of obesity and life style-related diseases related to obesity.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention refers to sunscreen products, cosmetic or pharmaceutical preparations or homecare products having UVA and/or UVB protection comprising an inorganic UV-filter and a certain mycosporine-like amino acid compound. The products and preparations provide improved SPF performance and UVA photoprotection. In addition, the products and preparations according to the present invention provide broad-spectrum photo-protection from UV radiation. Additionally, the present invention relates to the use of such mycosporine-like amino acid compound for boosting SPF and UVA photoprotection of a sunscreen product, cosmetic or pharmaceutical preparation or homecare product comprising an inorganic UV-filter. Furthermore, the present invention relates to a method of enhancing the SPF and UVA photoprotection of a sunscreen product, cosmetic or pharmaceutical preparation or homecare product comprising an inorganic UV-filter by the addition of a certain mycosporine-like amino acid compound. Finally, the present invention relates to a method for providing anti-aging benefits to skin, whitening or preventing darkening of skin, improving the appearance of skin, diminishing the visible signs of skin aging and improving skin&#39;s radiance and firmness by topically applying the sunscreen product, cosmetic or pharmaceutical preparation or homecare product according to the present invention to the skin.
Tetrahydroquinoxaline derivatives and their use in detecting C-kit G-quadruplex DNA and inhibiting gastrointestinal stromal tumors. The invention discloses a compound shown in a structural formula (I), wherein R &#39; is hydrogen or alkyl of C1-C18, and R &#39; &#39; is alkyl of C1-C18. The compounds of the invention can realize ratio-type detection of G4 DNA. The ratio type detection is not influenced by the concentration of a substrate and a probe, the external environment, the condition change of an instrument and the like, and can effectively avoid background interference and false positive during detection, thereby realizing the accurate detection of the G4 DNA. The compound (I) has good effect of stabilizing C-kit G4DNA, can inhibit gastrointestinal stromal tumor cell strains at a gene level in a targeted manner, and is expected to be developed into an effective medicament for preventing and treating gastrointestinal stromal tumors. 。
1,091,076. Encapsulating liquids. PILOT MAN-NEN-HITSU KABUSHIKI KAISHA. Oct. 21, 1964 [Oct. 21, 1963; Sept. 9, 1964 (2)], No. 43024/64. Heading B8C. [Also in Division G2] Droplets of hydrophilic liquid are encapsulated by preparing a first and a second liquid phase comprising, respectively, a hydrophobic liquid or a solution or dispersion in such a liquid and an hydrophilic liquid or a solution or dispersion in such a liquid, the two liquid phases being substantially immiscible and each comprising a substance which is capable of reacting with a substance in the other phase to form a polymer which is insoluble in both phases, and dispensing the said second liquid phase as droplets in the said first liquid phase to cause a reaction at the interfaces between the phases whereby the hydrophilic liquid droplets are enveloped in a polymer coating. Numerous reactive &#34; couples &#34; are disclosed which react to form condensation type polymers e.g. hydrophobic low molecular compounds or prepolymers having two or more functional groups such as -CNS, -CNO, -CO-Hal, -NH 2 , -SO 2 Cl, epoxy, halogen and chloroformate groups (in the hydrophobic phase) and a hydrophilic compound or prepolymer containing two or more functional groups such as -OH, -NH, -NH 2 , -SH, epoxy or methylol groups (in the hydrophilic phase). In this case the reactants from both phases react to form a polymer at the interfaces. Alternatively, one phase may contain a prepolymer or precondensate and the second phase may contain a polymerization catalyst (either the catalyst or prepolymer being hydrophobic) or the hydrophobic phase may contain a low molecular compound having two or more different functional groups, one being an amino or imino group and the other being an acid chloride or chloroformate group which undergoes selfcondensation in the presence of a hydrogen ion acceptor (e.g. an alkali) which is contained in the hydrophilic phase. Specific examples relate to the encapsulation of hydrophilic liquids containing a dye, a fertilizer composition, a photographic fixing agent, an epoxy resin setting agent, an electrolytic material (NaCl) and water.